Fast Growing Ceva Smashes 1bn Barrier



Fast-growing Ceva smashes 1bn barrier
13th February 2018

By Karen Pickwick
Ceva Santé Animale (Ceva) achieved growth of 20% and broke the billion euro barrier for the first time in 2017 with sales of €1.1bn. This performance consolidates its position as the sixth largest animal health company and leading French multinational in the sector.
Performance was strong across all geographical regions, with global sales split as follows: Europe 34%, Africa-Middle East-Eastern Europe-Turkey 19%, North America-Pacific 16%, Latin America 15% and Asia 13%.
In terms of product portfolios, companion animals sales grew 12% (29% of turnover) with poultry up 8%, (35% of turnover).
Delighted Ceva chairman and CEO Dr Marc Prikazsky said: “Our strong growth can be explained largely through our most recent acquisitions, Hertape and Inova in Brazil, but equally the purchase of a number of ex-Merial products and the acquisitions of Ebvac, China, Polchem in India and Biovac, France. However, our organic growth was also a driver, achieving an historic 9% increase (at constant scope and exchange rates). This success is due to the hard work of all our teams, in particular those in Libourne, for the smooth integration of these new companies, as well as the R&D, industrial and logistics teams for the development of such innovative new products as Feliscratch by Feliway, Zeleris and Smartvac.”
Ceva intends to maintain its strong dynamic through innovation and major global investment in its industrial sites.
“In these times of rapid global change, we need to make the most of our agility to quickly integrate, from today, the new orientations of research in areas such as artificial intelligence, connected agriculture, robotisation, digitalisation, big data, etc,” Marc said. “The challenge for the future will be how to integrate these new technologies into our business model. This is a challenge for the agricultural community as a whole, both in France and around the world. In all these areas, once again, Ceva wants to become a first-line reference.”
This year will see the realisation of three major projects in France under the ‘Factory of the Future’ banner:
Construction in Laval, Mayenne of a global centre of expertise in companion animals. Between 2014 and 2020 Ceva will have invested €25m in the Ceva Sogeval Campus, with €7.5m of that going towards the construction of an ultramodern 3600m2 campus – including a 1000m2 laboratory and Quality Control building 
Construction of a 2000m2 building in Loudéac, Brittany. Ceva has invested €6.8m in order to integrate a range of dermatological products for Companion animals. In addition to the Feliway and Adaptil ranges, it will produce the Douxo range for the European market, with the aim of becoming the world leader in topical dermatology products by 2020 (due to open in May 2018)
Construction of a 2600m2 industrial building in Libourne, Gironde. With an investment of €8.5m, the Group hopes to increase storage capacity for vaccines and, at the same time, improve its logistics (due to open in November 2018). This year, Ceva will also initiate a project to examine how to reorganise the entire Libourne site, which includes its head office, with the aim of improving the work environment and encouraging exchange between different services.
“To maintain its constant rhythm of growth, it is imperative that Ceva continues to invest in the future, in innovation, in new sectors like biotechnology and in R&D – particularly in relation to swine and poultry biology,” Marc concluded.